Article Tools
REVIEW ARTICLES
Article Tools
High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management
, MBBS, MD, DM, PhD1; Martin Dreyling, MD, PhD2; John F. Seymour , MBBS, PhD3; and Michael Wang, MD1 Show More
Conception and design: Preetesh Jain, Michael Wang
Collection and assembly of data: All authors
Data analysis and interpretation: All authors
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
Consulting or Advisory Role: Acerta Pharma/AstraZeneca, Bayer/Vital, Celgene/Jazz, Gilead Sciences, Janssen-Cilag, Novartis, Roche, Beigene
Speakers' Bureau: Bayer Health, Celgene, Gilead Sciences, Janssen-Cilag, Roche Pharma AG
Research Funding: Celgene (Inst), Janssen-Cilag (Inst), Roche Pharma AG (Inst), AbbVie (Inst)
Travel, Accommodations, Expenses: Celgene, Janssen-Cilag, Roche Pharma AG
Honoraria: AbbVie, Acerta Pharma, Janssen, Roche, Sunesis Pharmaceuticals, Takeda
Consulting or Advisory Role: AbbVie, Acerta Pharma, Janssen, Roche, Sunesis Pharmaceuticals, Takeda, AstraZeneca, Bristol-Myers Squibb, Gilead Sciences, MEI Pharma, MorphoSys
Speakers' Bureau: AbbVie, Roche
Research Funding: AbbVie, Celgene, Janssen, Roche
Expert Testimony: Roche
Travel, Accommodations, Expenses: AbbVie, Roche
Stock and Other Ownership Interests: MoreHealth
Honoraria: Janssen Research & Development, DAVAOncology, OMI, PeerView Institute for Medical Education (PVI), OBR Oncology, Onclive, Pharmacyclics, AstraZeneca, Targeted Oncology
Consulting or Advisory Role: AstraZeneca, Janssen Research & Development, Celgene, MOREhealth, Juno Therapeutics, BioInvent International, Pharmacyclics/Janssen, Pulse Biosciences, AxImmune, Kite Pharma, Guidepoint Global, Loxo, InnoCare, Oncternal Therapeutics
Research Funding: AstraZeneca, Janssen Research & Development, Pharmacyclics, Kite Pharma, Juno Therapeutics, BeiGene, Acerta Pharma, Oncternal Therapeutics, BioInvent International, Loxo, VelosBio, Celgene, Verastem, InnoCare, Molecular Templates, Eli Lilly
Travel, Accommodations, Expenses: Janssen Research & Development, AstraZeneca, Celgene, DAVAOncology, OMI
No other potential conflicts of interest were reported.
